Diagnostic and prognostic value of fecal, serum and endoscopic markers in inflammatory bowel disease and colorectal cancer
Background. The most important goals of the recent therapies of inflammatory bowel disease (IBD) are to induce and maintain clinical remission and mucosal healing (MH), which can be achieved with anti-TNF-α biological therapy. CT-P13 is the first biosimilar to infliximab (IFX) that has been approved...
Elmentve itt :
| Szerző: | |
|---|---|
| További közreműködők: | |
| Dokumentumtípus: | Disszertáció |
| Megjelent: |
2018-06-14
|
| Kulcsszavak: | mucosal healing, biosimilar infliximab, infliximab serum level, infliximab antibody |
| Tárgyszavak: | |
| doi: | 10.14232/phd.9839 |
| mtmt: | 30612581 |
| Online Access: | http://doktori.ek.szte.hu/9839 |